aTYR PHARMA (ATYR) Assets Average (2015 - 2026)

aTYR PHARMA (ATYR) has reported Assets Average for 12 consecutive years, with $74.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 24.8% year-over-year to $74.7 million; the trailing twelve-month figure through Jun 2026 stood at $74.7 million (down 24.8% YoY), and the FY2025 full-year result was $94.9 million, down 12.71% from the prior year.
• Assets Average fell to $74.7 million in Q2 2026 per ATYR's latest filing, from $86.3 million in the prior quarter.
• Across five years, Assets Average topped out at $134.8 million in Q2 2023 and bottomed at $74.7 million in Q2 2026.
• Historically, Assets Average has averaged $104.8 million across 5 years, with a median of $100.1 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Assets Average jumped 134.74% in 2022, then dropped 24.8% in 2026.
• Over 5 years, Assets Average stood at $95.9 million in 2022, then rose by 28.09% to $122.9 million in 2023, then decreased by 23.31% to $94.2 million in 2024, then grew by 5.95% to $99.8 million in 2025, then slipped by 25.13% to $74.7 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $74.7 million, $86.3 million, and $99.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.